[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

ENTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.90%

Insider Buying (Last 12 Months): $32,274.47

Insider Selling (Last 12 Months): $0.00

Entera Bio Insider Trading History Chart

Entera Bio Share Price & Price History

^$1.59

▼ -0.03 (-1.85%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

Let’s be blunt

From DTI | Ad

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now

Entera Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2024	Haya Taitel	Director	Buy	9,500	$0.99	$9,405.00	35,115
1/10/2024	Haya Taitel	Director	Buy	7,615	$0.77	$5,863.55	25,615
12/22/2023	Miranda Jayne Toledano	CEO	Buy	23,952	$0.71	$17,005.92	110,752
8/21/2023	Sean Ellis	Director	Buy	40,000	$0.60	$24,000.00	102,100
4/4/2023	Miranda Jayne Toledano	CEO	Buy	30,000	$1.01	$30,300.00	86,800
11/11/2022	Miranda Jayne Toledano	CEO	Buy	50,000	$0.53	$26,500.00	56,800
11/11/2022	Sean Ellis	Director	Buy	30,000	$0.53	$15,900.00	62,100
7/21/2022	Sean Ellis	Director	Buy	14,900	$1.64	$24,436.00	32,100
1/19/2022	Ramesh Ratan	CFO	Buy	10,000	$2.44	$24,400.00
1/18/2022	Ron Mayron	Director	Buy	7,000	$2.80	$19,600.00
1/13/2022	Yonatan Malca	Director	Buy	7,232	$2.74	$19,815.68

New post-election stock warning from Wall Street

From Chaikin Analytics | Ad

If you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first time in history...

Not everything is as rosy as it seems on Wall Street.

SEC Filings (Institutional Ownership Changes) for Entera Bio (NASDAQ:ENTX)

14.11% of Entera Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Entera Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	Parkman Healthcare Partners LLC	411,076	$0.78M	0.1%	+2.4%	1.149%
11/6/2024	Signature Estate & Investment Advisors LLC	47,328	$90K	0.0%	N/A	0.132%
8/9/2024	Renaissance Technologies LLC	57,600	$0.11M	0.0%	-23.1%	0.161%
5/20/2024	Virtu Financial LLC	22,040	$37K	0.0%	N/A	0.000%
2/14/2023	RA Capital Management L.P.	295,966	$0.22M	0.0%	-85.8%	1.028%
11/14/2022	RA Capital Management L.P.	2,082,372	$2.17M	0.0%	-11.5%	7.229%
1/31/2022	Altium Wealth Management LLC	11,830	$33K	0.0%	N/A	0.050%
1/28/2022	ARK Investment Management LLC	690,922	$1.95M	0.0%	+1.2%	2.915%
8/17/2021	Knoll Capital Management LLC	2,484,275	$14.86M	7.8%	+38.7%	10.482%
8/16/2021	RA Capital Management L.P.	2,353,000	$14.07M	0.2%	N/A	9.928%
8/13/2021	Geode Capital Management LLC	17,597	$0.11M	0.0%	N/A	0.074%
8/11/2021	Susquehanna Fundamental Investments LLC	14,400	$86K	0.0%	N/A	0.061%
6/14/2021	Knoll Capital Management LLC	1,791,363	$6.83M	4.4%	+2.9%	7.558%
5/18/2021	Millennium Management LLC	38,611	$0.15M	0.0%	N/A	0.163%
5/14/2021	XTX Topco Ltd	11,559	$44K	0.0%	N/A	0.101%
5/13/2021	Renaissance Technologies LLC	120,407	$0.46M	0.0%	+66.8%	1.053%
2/24/2021	Virtu Financial LLC	31,314	$34K	0.0%	N/A	0.274%
2/10/2021	Renaissance Technologies LLC	72,186	$78K	0.0%	N/A	0.632%

Data available starting January 2016

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $1.59

$1.57

$1.65

50 Day Range

MA: $1.83

$1.55

$2.12

52 Week Range

Now: $1.59

$0.52

$3.35

Volume

35,684 shs

Average Volume

132,411 shs

Market Capitalization

$56.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Who are the company insiders with the largest holdings of Entera Bio?: Entera Bio's top insider shareholders include:
Miranda Jayne Toledano (CEO)
Sean Ellis (Director)
Haya Taitel (Director)
Learn More about top insider investors at Entera Bio.
Who are the major institutional investors of Entera Bio?: Entera Bio's top institutional investors include:
Parkman Healthcare Partners LLC — 1.15%
Signature Estate & Investment Advisors LLC — 0.13%
Learn More about top institutional investors of Entera Bio stock.
Which major investors are buying Entera Bio stock?: During the previous quarter, ENTX stock was purchased by institutional investors including:
Signature Estate & Investment Advisors LLC
Parkman Healthcare Partners LLC
Within the previous year, these company insiders have bought Entera Bio stock:
Miranda Jayne Toledano (CEO)
Sean Ellis (Director)
Haya Taitel (Director)
Learn More investors buying Entera Bio stock.